Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice

Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice

Clinical anti-drug-antibody (ADA) responses represent a substantial obstacle to the development of efficacious therapeutic antibodies. The enhanced ADA production against the idiotype (Id) often displayed by cancer immunotherapy antibodies (CitAbs) can lead to exposure loss and subsequently affect a...

Full description

Bibliographic Details
Main Authors:	Jerome Egli, Stefan Heiler, Felix Weber, Guido Steiner, Timo Schwandt, Katharine Bray-French, Christian Klein, Sebastian Fenn, Gregor P. Lotz, Eugenia Opolka-Hoffmann, Thomas E. Kraft, Laetitia Petersen, Rebecca Moser, Jonathan DeGeer, Michel Siegel, Daniela Finke, Juliana Bessa, Antonio Iglesias
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-12-01
Series:	mAbs
Subjects:	ADA idiotype immunogenicity linked-antigen tolerance FcRn Fc-tolerance
Online Access:	https://www.tandfonline.com/doi/10.1080/19420862.2022.2143009

Similar Items

The Immature Gut Barrier and Its Importance in Establishing Immunity in Newborn Mammals
by: Björn Weström, et al.
Published: (2020-06-01)

FcRn Expression in Wildtype Mice, Transgenic Mice, and in Human Tissues
by: Tommy Li, et al.
Published: (2018-10-01)

Harnessing Fc/FcRn Affinity Data from Patents with Different Machine Learning Methods
by: Christophe Dumet, et al.
Published: (2023-03-01)

Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis
by: Thomas E. Kraft, et al.
Published: (2020-01-01)

Oral Fc-Coupled Preproinsulin Achieves Systemic and Thymic Delivery Through the Neonatal Fc Receptor and Partially Delays Autoimmune Diabetes
by: Noémie Corcos, et al.
Published: (2021-08-01)

The Dual Targeting of FcRn and FcγRs via Monomeric Fc Fragments Results in Strong Inhibition of IgG-Dependent Autoimmune Pathologies
by: Céline Monnet, et al.
Published: (2021-08-01)

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024-12-01)

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
by: Takuo Suzuki, et al.
Published: (2021-01-01)

The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer
by: Justin Thomas, et al.
Published: (2022-06-01)

Megalin Orchestrates FcRn Endocytosis and Trafficking
by: Eileen Dahlke, et al.
Published: (2022-12-01)

Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker
by: Yihan Zhou, et al.
Published: (2023-06-01)

Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents
by: Geert van Tetering, et al.
Published: (2020-12-01)

Anticalin N- or C-Terminal on a Monoclonal Antibody Affects Both Production and In Vitro Functionality
by: Nicolas Aubrey, et al.
Published: (2022-08-01)

IgG subclasses and allotypes: from structure to effector functions
by: Gestur eVidarsson, et al.
Published: (2014-10-01)

Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review
by: Yanis Ramdani, et al.
Published: (2022-08-01)

Human FcRn Is a Two-in-One Attachment-Uncoating Receptor for Echovirus 18
by: Xiangpeng Chen, et al.
Published: (2022-08-01)

Trafficking analyses of FcRn and IgG ligand in the post-Brambell era
by: E. Sally eWard, et al.
Published: (2015-07-01)

Advances in therapeutic Fc engineering - modulation of IgG associated effector functions and serum half-life
by: Abhishek Saxena, et al.
Published: (2016-12-01)

Opinion: There’s been a flaw in our thinking.
by: Clark Lawrence Anderson
Published: (2014-10-01)

Tissues Expression, Polymorphisms Identification of FcRn Gene and Its Relationship with Serum Classical Swine Fever Virus Antibody Level in Pigs
by: Liu Yang, et al.
Published: (2012-08-01)

Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance
by: Angelina Mimoun, et al.
Published: (2020-05-01)

Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates
by: Yvonne J. Rosenberg, et al.
Published: (2023-04-01)

Pemphigus Vulgaris: Present and Future Therapeutic Strategies
by: Dario Didona, et al.
Published: (2022-02-01)

Regulation of immune responses by the neonatal Fc receptor and its therapeutic implications
by: Timo eRath, et al.
Published: (2015-01-01)

Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
by: Simone Mester, et al.
Published: (2021-01-01)

Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions
by: Céline eMonnet, et al.
Published: (2015-02-01)

Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders
by: E. Sally Ward, et al.
Published: (2022-06-01)

Possible Mechanisms by Which Enzymatic Degradation of Human Serum Albumin Can Lead to Bioactive Peptides and Biomarkers
by: Ulrich Kragh-Hansen
Published: (2018-07-01)

An ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in cats
by: Chen Gilor, et al.
Published: (2021-09-01)

The contribution of cell surface FcRn in monoclonal antibody serum uptake from the intestine in suckling rat pups
by: Philip R Cooper, et al.
Published: (2014-10-01)

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
by: James F. Howard, et al.
Published: (2024-01-01)

Antibodies and their receptors: different potential roles in mucosal defence
by: Rachel eHorton, et al.
Published: (2013-07-01)

Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies
by: Hanine Rafidi, et al.
Published: (2022-12-01)

Fully human monoclonal antibody inhibitors of the neonatal Fc receptor (FcRn) reduce circulating IgG in nonhuman primates
by: Andrew E Nixon, et al.
Published: (2015-04-01)

FcRN receptor antagonists in the management of myasthenia gravis
by: Vinaya Bhandari, et al.
Published: (2023-08-01)

Human FcRn can mediate the transport across intestinal mucosal barrier and prolong the half-life of rabbit IgG in vivo
by: Guangchang Pang, et al.
Published: (2015-06-01)

Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium
by: João P. Martins, et al.
Published: (2022-03-01)

Antibody-mediated oral delivery of therapeutic DNA for type 2 diabetes mellitus
by: Seungbin Cha, et al.
Published: (2018-07-01)

Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia
by: Trang T. Vu, et al.
Published: (2024-01-01)

Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method
by: Thomas Müller, et al.
Published: (2023-12-01)